(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.86%.
Aldeyra Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ALDX's revenue for 2024 to be $5,942,155,100, with the lowest ALDX revenue forecast at $5,942,155,100, and the highest ALDX revenue forecast at $5,942,155,100. On average, 3 Wall Street analysts forecast ALDX's revenue for 2025 to be $2,116,179,696, with the lowest ALDX revenue forecast at $1,111,183,004, and the highest ALDX revenue forecast at $3,999,070,382.
In 2026, ALDX is forecast to generate $4,627,750,392 in revenue, with the lowest revenue forecast at $3,083,978,497 and the highest revenue forecast at $7,641,611,459.